Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leem president Christian Lajoux re-elected for third term

This article was originally published in Scrip

Executive Summary

Christian Lajoux has been elected for a third term as president of French pharmaceutical industry association Leem. Mr Lajoux is president of Sanofi-Aventis France and has been Leem's president since 1 July 2006; his new two-year term begins on 1 January 2011.

You may also be interested in...



Pharma Guidelines, ending 1 July 2011

Recently updated and newly issued documents

EuropaBio appoints new chairman

EuropaBio, the European biotech industry association, has appointed Stephan Tanda as its new association chair. Mr Tanda, a member of the managing board of life sciences and materials sciences firm DSM, succeeds GlaxoSmithKline's Andrea Rappagliosi, who will remain a member of the EuropaBio board.

Medtech Guidelines, ending 24 June 2011

Recently updated and newly issued documents

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC009283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel